Algernon Pharmaceuticals Inc (AGNPF)

[jb1965]

I agree with AMG that strategically it would have been better, from a risk diversification perspective, to have NaNose in the BTH portfolio. But it became clear (to me) that the technology faced challenges through the monthly report updates. There may have been a workable solution for a company with deep pockets. But if you have a 2 year run rate, you have to think differently.

I don't know anything about Owelstone apart from the fact they are competition from other's posts on this board. Do you they rely on NaNose or FAIMS technology?

JB